Prof. Adam Duerfeldt's Research Program Awarded New NIH Funding
September 20, 2024
Professor Adam S. Duerfeldt has been named the Primary Investigator on a new R21 NIH award entitled Bifunctional Inhibitors of STING as Chemical Probes for Diabetic Retinopathy!
This is in addition to another recent multi-PI research program with collaborators from Memorial Sloan Kettering, the University of Oklahoma, and Merck: Small-Molecule Penetration and Efflux in Gram-Negative Bacteria.
We are thrilled to see Prof. Duerfeldt’s success in securing these competitive and prestigious awards!
Read more about the Duerfeldt Lab.
Media Contacts
Related Stories
The Center for Drug Design (CDD), part of the University of Minnesota College of Pharmacy, created a novel technology using biomimetic decoy molecules to boost the skin's natural ability to mitigate ultraviolet-induced damage, a development that has the potential to revolutionize the skincare industry.
Held this year in St. Paul, the conference brings together a diverse and global community of researchers involved in basic, clinical, and translational retinoid research.
Prof. Ambrose was invited to speak at the event, hosted at the University of Bonn (Germany), due to her expertise with the chemical exploration and analysis of Baltic amber.